19:17:03 EDT Sun 07 Aug 2022
Enter Symbol
or Name

Login ID:

Innocan Pharma Announces 100% Exercise of Warrants Issued in December 2020 Private Placement

2021-11-05 04:01 ET - News Release

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 5, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan) is pleased to announce that all investors who participated in the Company's December 2020 private placement (the "Offering") fully exercised the common share purchase warrants (the "Warrants") issued to them as part of the Offering. The exercise of the Warrants by the investors resulted in a total cash receipt for the Company of approximately CAD $1.4 million and resulted in the issuance of 3,998,705 common shares of the Company. This marks the completion of the third round of warrant exercises in two years.

Pursuant to the terms of the Warrants, the Company had the right to issue a notice to accelerate the expiry date of the Warrants if the daily volume weighted average trading price of the Company's shares on the Canadian Securities Exchange equaled or exceeded $0.70 for any period of 30 consecutive trading days.

"This remarkable achievement demonstrates a much-appreciated act of trust and confidence from our investors," said Iris Bincovich, CEO of Innocan Pharma. "We are excited that our investors have enjoyed the appreciation of their initial investment, and in addition they have decided to invest more. We are humbled by the continued support of our investor community, as Innocan Pharma continues to grow and secure its place as an innovator within the CBD space."

Innocan's relationship with The Hebrew University

Innocan Pharma Ltd., a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("Yissum"), the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization, and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over fifty-five patent families, two of which underlie Doxil®, an FDA-approved drug for breast cancer treatment. This unique platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation, and central nervous system disorders. A patent application was filed covering this technology on September 30, 2021.

About Innocan

Innocan, together with its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled slow release Technologies to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

Lytham Partners, LLC
Ben Shamsian CPA | Vice President

Direct: 646-829-9701; Cell: 516-652-9004



Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals, the granting of patents underlying the patent applications and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; intellectual property risks, and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102064

© 2022 Canjex Publishing Ltd. All rights reserved.